Presented by:
Michael Teitell, M.D., Ph.D.
Professor, Department of Pathology and Laboratory Medicine
Director, JCCC Cancer Nanotechnology Program Area

Dr. Michael Teitell’s lab is interested in molecular mechanisms of malignant transformation, with an emphasis on germinal center derived B-cell lymphomas. A screen that compared gene expression profiles from B-cell lymphomas in immune deficient versus immune competent settings identified TCL1 as a dysregulated oncogene in a large number of B-cell leukemias and lymphomas. Generation of a TCL1 transgenic mouse, in which TCL1 expression was maintained throughout B- and T-cell development, lead to one of the first genetic models for germinal center B-cell lymphomas and less frequently B- and T-cell chronic lymphocytic leukemias.

Light lunch served

Sponsored by the JCCC Cancer Nanotechnology Program Area